lambrini girl
09 Feb 2016
Re: Neil Woodford parts of biotech in bu... this shudd drop to 365 ...<<<BANG ON!!
Stepenwolf
19 Jan 2016
Re: What happened? All of the above I think. Worse still, I bought some IBT and BIOG before the recent drops.
donkeyjawbone
19 Jan 2016
Re: What happened? Lol, SW, don't worry about that. At least we're back in the blue if only just. Which gives me the courage to come back here to check what's new. Must have had too much wine over the festive season. These falls took me completely by surprise.Yeah I know IBT and BIOG follow the NASDAQ. But why is the NASDAQ falling? Is it because everything else is falling? Seasonal affective disorder? Chinese stock market trouble? Falling oil prices?
Stepenwolf
13 Jan 2016
Re: What happened? Me and my big mouth - now the index is down 2.7% !
Stepenwolf
13 Jan 2016
Re: What happened? HiI think the fall is due to successive days falls, over the last few days. in the US NASDAQ BIOTECH Index. Here is link [link] tends to happen is that the IBT and other BIOTECH trust share follow the NASDAQ up and down. Yesterday the index was up 1.47% so would expect some sort of positive move in the IBT
donkeyjawbone
12 Jan 2016
What happened? What's the reason for today's massive fall?
Kingel
13 Oct 2015
Why I'm holding on to my biotech trusts [link]
sage in the hills
28 Aug 2015
This will continue ...... ..... to be a very well managed fund, with the managers sifting out the profits, weeding out the stallers, and sowing new seed,as an ongoing process.nature there will be volatility.The success of this fund is in its sharp short term and long term management.SAGE
lambrini girl
27 Aug 2015
Re: Neil Woodford parts of biotech in bubble WOW!!///Woodie very observant...this shudd drop to 365 by next summer...
Kingel
05 Aug 2015
Neil Woodford parts of biotech in bubble Video[link]
Kingel
05 Aug 2015
David Kempton: how I'm buying biotech Experienced private investor David Kempton outlines his approach to investing in biotechnology and explains why he is investing in more house builders and 'challenger' banks.I frequently adopt the same approach to buying risky technology and biotechnology stocks as I do with oil explorers. It is so difficult and time consuming to do your own due diligence, so I follow an ‘in form’ expert professional, whose team will have done all that work for you, or buy a fund. The latter won’t be as exciting (although my holding in the International Biotechnology (IBT ) investment trust has doubled in 12 months), but it is a much safer option. Alternatively I buy several stocks to spread the risk. Of any six, two may die, two could boringly rattle along with constant promises of jam tomorrow and two will hit the jackpot. I’m sticking with IBT, now a large holding, but have also bought a biotech stock held by Neil Woodford, who currently seems to walk on water. ReNeuron (RQE) is a leading UK cell therapy company focusing on a nanomedicine cancer programme. You may understand the implications of that, but I don’t. However, I do understand that it is in the vanguard of biotech companies in London. Having successfully completed a phase one clinical trial in stroke victims, it is now embarking on phase two, from which results will be available by the end of the year.So when they raised £68 million two weeks ago at a very ambitious 5p, and Woodford increased his fund's holding from 26% to 35%, I bought some more – effectively a blue sky gamble, but actually following a man whose team will have done all the diligence.There has always been more US appetite for speculative biotech and small pharmaceutical companies, but recently the UK has come to accept the much higher risk reward ratio that comes with these stocks, and suddenly we have a rush of new initial public offerings coming to the sector.Encouraged by this I have also bought OptiBiotix (OPTI), set up three years ago to develop products which can improve health by altering the way microbes work and react in the body. Clinical trials have gone well and the human trial results are due in September, whilst good progress has been made in building a potentially exciting sustainable business. The board members are experts in biotech, and well-respected fund group Seneca Partners has just bought 8.5%.I confess to a somewhat selfish reason for investing in this sector; it is just possible that some new development may extend my life or, more likely, those of my children, and without the support of shareholders, these companies may not exist.[link]
Kingel
19 Jul 2015
Biotech scales new heights Meanwhile, the astonishing run of biotechnology investment trusts gathered strength this week, as heightened mergers and acquisition activity helped companies in the sector scale the next leg of its multi-year bull run.While there have been jitters on the way, biotech stocks, and the trusts that invest in them, look set to notch up their fourth successive year of standout gains.The five-year share price returns of the three pure biotech investment trusts are staggering: BB Biotech (BION.S) is up 551.6%, Biotech Growth (BIOG + ) has grown 488.1% and International Biotechnology (IBT + ) has risen 320%.This week, they were again among the top performing investment trust shares. BB Biotech of Switzerland jumped 10.1% while UK-listed Biotech Growth and Worldwide Healthcare (WWH + ), both run by OrbiMed Advisers in the US, rose 6.3% and 5.8% respectively.The sector has consistently confounded those who argue biotech stocks have risen too far. Each time the sector has suffered a setback, such as in April last year and July, when US Federal Reserve chair Janet Yellen argued valuations had become ‘stretched’, it has come back stronger.Buyouts are helping biotech stocks hit new heights this year. Reuters estimates that around €250 billion (£160 billion) of deals have been completed in the healthcare sector in 2015, with US group Celgene’s (CELG.O) $7.2 billion takeover of peer Receptos (RCPT.O) the latest.Shares in Receptos jumped 11% in Wednesday’s trading, providing a particular boost for BB Biotech, which is the company’s third largest fund shareholder. Biotech Growth has a smaller stake, while all three trusts are invested in Celgene, whose shares also rose, up 7% on the news.When Biotech Growth last month celebrated its 10th birthday OrbiMed didn't betray any nervousness over the lofty levels of biotech stocks. Fund manager Sven Borho said earnings growth was spurring share price gains, rather than a bubble forming around the sector. ‘Biotech has seen four years of consistent outperformance versus [the S&P 500] and this has largely been driven by earnings and sales growth in the industry,’ he said.‘We are very optimistic and we believe investment opportunities and valuation in biotech are here to set the stage for the next 10 years.’[link]
brownsfriend
16 Jun 2015
The time has come Enjoyed the huge ride up in IBT and now just sold GILD only CELG left in Bio - just a feeling that the time has come for a major correction - valuations much too stretched - can see profits disappear so not being greedy maybe another small leg up in this bubble but for me the time has come!! SELL IMHO
knight1307
06 May 2015
Re: Investment Insider Just bought in at 514 seem a good move technically, just hope the sector keeps out performing.
Kingel
02 Apr 2015
Investment Insider BUY BUY or BYE BYE Bio's[link]
